INVIVYD INC (IVVD) competitors & alternatives
Health Care · NASDAQ
INVIVYD INC (IVVD)'s top competitors and alternatives — its most similar public companies — include Lilly (Eli) (LLY), Regeneron Pharmaceuticals (REGN), ZENAS BIOPHARMA INC (ZBIO), Z SQUARED INC (ZSQR), Pfizer (PFE), Moderna (MRNA), ENANTA PHARMACEUTICALS INC (ENTA), JADE BIOSCIENCES INC (JBIO), SPYRE THERAPEUTICS INC (SYRE), SHATTUCK LABS INC (STTK), CONNECT BIOPHARMA HOLDINGS LTD (CNTB) and ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT). These are INVIVYD INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top IVVD competitors & alternatives
-
Lilly (Eli)LLYHealth Care
A global pharmaceutical powerhouse developing innovative medicines across cardiometabolic, oncology, and immunology with blockbuster GLP-1 and weight-loss…
$1,163.01 (as of 2026-07-22) · market cap $1.09T
-
Regeneron PharmaceuticalsREGNHealth Care
Regeneron develops and commercializes monoclonal antibody and other biologics therapies across immunology, oncology, infectious disease, and other therapeutic…
$651.18 (as of 2026-07-22) · market cap $70.6B
-
ZENAS BIOPHARMA INCZBIOHealth Care
Zenas BioPharma is a clinical-stage immunology company developing obexelimab, a novel bifunctional B cell-inhibiting monoclonal antibody, and orelabrutinib, a…
$31.49 (as of 2026-07-22) · market cap $2.0B
-
Z SQUARED INCZSQRHealth Care
An early-stage biopharmaceutical company developing natural killer cell therapies and CAR platforms for cancer and infectious diseases, complemented by…
$4.98 (as of 2026-07-22) · market cap $293M
-
PfizerPFEHealth Care
Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular,…
$24.82 (as of 2026-07-22) · market cap $142.0B
-
ModernaMRNAHealth Care
Moderna is an unprofitable mRNA vaccine and therapeutic company pivoting from peak COVID revenues with a diversified pipeline facing intense competition and…
$58.07 (as of 2026-07-22) · market cap $22.9B
-
ENANTA PHARMACEUTICALS INCENTAHealth Care
A biotechnology company leveraging small molecule discovery to treat viral and liver diseases, supported by recurring HCV royalty streams.
$13.06 (as of 2026-07-22) · market cap $390M
-
JADE BIOSCIENCES INCJBIOHealth Care
Jade Biosciences is a clinical-stage biotech developing next-generation monoclonal antibodies with extended half-lives to treat autoimmune diseases like IgA…
$19.85 (as of 2026-07-22) · market cap $1.2B
-
SPYRE THERAPEUTICS INCSYREHealth Care
Spyre is developing a portfolio of long-acting engineered antibodies and combinations targeting validated inflammatory pathways in IBD and rheumatic diseases…
$99.17 (as of 2026-07-22) · market cap $8.6B
-
SHATTUCK LABS INCSTTKHealth Care
Shattuck Labs is a clinical-stage biotech developing novel protein therapeutics to treat inflammatory and immune-mediated diseases by targeting the DR3/TL1A…
$7.02 (as of 2026-07-22) · market cap $634M
-
CONNECT BIOPHARMA HOLDINGS LTDCNTBHealth Care
Clinical-stage biopharmaceutical company developing rademikibart, an IL-4Rα-targeting monoclonal antibody to treat acute exacerbations of asthma and COPD.
$2.20 (as of 2026-07-22) · market cap $139M
-
ARCTURUS THERAPEUTICS HOLDINGS INCARCTHealth Care
Arcturus Therapeutics develops self-amplifying mRNA therapeutics and vaccines, with the first approved sa-mRNA COVID vaccine (KOSTAIVE) generating revenue…
$5.93 (as of 2026-07-22) · market cap $168M
Not quite? Describe exactly what you want →
Peers are INVIVYD INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: INVIVYD INC (IVVD).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.